In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

We compared the susceptibility of multidrug-resistant isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mut...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2021-05, Vol.65 (6)
Hauptverfasser:	Rubio, Abigail M, Kline, Ellen G, Jones, Chelsea E, Chen, Liang, Kreiswirth, Barry N, Nguyen, M Hong, Clancy, Cornelius J, Cooper, Vaughn S, Haidar, Ghady, Van Tyne, Daria, Shields, Ryan K
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Cephalosporins - pharmacology Drug Resistance, Multiple, Bacterial - genetics Humans Mechanisms of Resistance Microbial Sensitivity Tests Pseudomonas aeruginosa - genetics Pseudomonas Infections - drug therapy Tazobactam - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We compared the susceptibility of multidrug-resistant isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in among 79% (11/14) of paired isolates. mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with mutations were susceptible to imipenem-relebactam.
ISSN:	0066-4804 1098-6596
DOI:	10.1128/AAC.00084-21